Merit Medical Systems (MMSI)
(Delayed Data from NSDQ)
$73.78 USD
+0.40 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
+0.40 (0.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $73.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Zacks News
Here's Why You Should Add HealthEquity (HQY) to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.
MMSI vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
MMSI vs. ALGN: Which Stock Is the Better Value Option?
Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility
by Zacks Equity Research
Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.
Modular Medical (MODD) Pairing Technology Issued New U.S. Patent
by Zacks Equity Research
Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
DexCom (DXCM) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results are likely to reflect rising volumes across all channels.
Labcorp (LH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Labcorp's (LH) fourth-quarter 2023 performance is likely to have demonstrated strength across its core businesses.
GE HealthCare (GEHC) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance, driven by consistent NPIs and growing customer demand.
Why Merit Medical (MMSI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Merit Medical (MMSI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BD's (BDX) Tie-Up to Offer AI-Based Digital System for Pap Test
by Zacks Equity Research
BD's (BDX) latest partnership is likely to aid cytotechnologists and pathologists to efficiently identify evidence of cervical cancer and pre-cancerous lesions.
Here's Why Merit Medical (MMSI) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Should You Buy Merit Medical (MMSI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
What's in Store for Cardinal Health (CAH) in Q2 Earnings?
by Zacks Equity Research
Cardinal Health's (CAH) second-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.
STERIS (STE) Set to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2024 results are likely to reflect solid performance across both the Healthcare and AST segments.
IDEXX Laboratories (IDXX) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses are likely to have boosted IDEXX Laboratories' (IDXX) revenues in Q4.
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited fiscal first-quarter sales.